Pr BAUMERT Thomas
Fiche personne
coordonnées
Institut de Recherche sur les Maladies Virales et Hépatiques
3 rue Koeberlé
67000 STRASBOURG
03 68 85 37 03
Territoire
Alsace
Statut
Hospitalo-Universitaire
affiliation
Hôpitaux universitaires de Strasbourg (CHRU Strasbourg)
Inserm UMR_S 1110 - Institut de Recherche sur les Maladies Virales et Hépatiques (Inserm UMR_S1110)
équipes/plateformes
Recherche
Expertises :
- Cancer:Foie
- Recherche:Virologie
Projets
Equipement Vevo 3100 Preclinical Imaging System
2019 - Porteur du projet : Pr BAUMERT Thomas
Médecine de précision de nouvelle génération pour la prévention et le traitement du carcinome hépatocellulaire (TheraHCC 2.0)
2019 - Porteur du projet : Pr BAUMERT Thomas
Single cell RNASeq of hepatocellular carcinoma: heterogeneity, microenvironment and therapeutic targets
2018 - Porteur du projet : Pr BAUMERT Thomas
Carcinome hépato-cellulaire – de la pathogénèse moléculaire à la prise en charge clinique (Thera HCC)
2014 - Porteur du projet : Pr BAUMERT Thomas
Carcinome hépato-cellulaire – de la pathogénèse moléculaire à la prise en charge clinique (Thera HCC)
2013 - Porteur du projet : Pr BAUMERT Thomas
Nanovectors for imaging and gene silencing based therapy of hepatocellular carcinoma (NanoISI)
2012 - Porteurs du projet : Pr BAUMERT Thomas, Dr VOEGEL Jean-Claude
Publications
Single-cell RNA-sequencing of virus-specific cellular immune responses in chronic hepatitis B patients.
Hatje K, Kam-Thong T, Giroud N, Saviano A, Simo-Noumbissie P, Kumpesa N, Nilsson T, Habersetzer F, Baumert TF, Pelletier N, Forkel M
Sci Data. 2024 04 8;11(1):355
Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNASeq.
Tonnerre P, Baumert TF
J Hepatol. 2024 03 19;:
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension.
Petrenko O, Königshofer P, Brusilovskaya K, Hofer BS, Bareiner K, Simbrunner B, Jühling F, Baumert TF, Lupberger J, Trauner M, Kauschke SG, Pfisterer L, Simon E, Rendeiro AF, de Rooij LPMH, Schwabl P, Reiberger T
iScience. 2024 03 15;27(3):109301
Comparative analysis of human, rodent and snake deltavirus replication.
Khalfi P, Denis Z, McKellar J, Merolla G, Chavey C, Ursic-Bedoya J, Soppa L, Szirovicza L, Hetzel U, Dufourt J, Leyrat C, Goldmann N, Goto K, Verrier E, Baumert TF, Glebe D, Courgnaud V, Gregoire D, Hepojoki J, Majzoub K
PLoS Pathog. 2024 03 5;20(3):e1012060
The gut microbiome as a guidepost for infection risk in liver transplantation.
Vieira AT, Baumert TF
Cell Host Microbe. 2024 01 10;32(1):9-11
Left-sided portal hypertension: Update and proposition of management algorithm.
Mayer P, Venkatasamy A, Baumert TF, Habersetzer F, Pessaux P, Saviano A, Felli E
J Visc Surg. 2023 12 22;:
Inflammation-related prognostic markers in resected hepatocellular carcinoma.
Giannone F, Slovic N, Pessaux P, Schuster C, Baumert TF, Lupberger J
Front Oncol. 2023 12 7;13:1267870
JAK1 promotes HDV replication and is a potential target for antiviral therapy.
Heuschkel MJ, Bach C, Meiss-Heydmann L, Gerges E, Felli E, Giannone F, Pessaux P, Schuster C, Lucifora J, Baumert TF, Verrier ER
J Hepatol. 2023 11 2;:
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B.
Faure-Dupuy S, Baumert TF
Hepatol Int. 2023 06 27;:
Memories of Stress: The Imprinted Cancer Risk After HCV Cure.
Lupberger J, Baumert TF
Cell Mol Gastroenterol Hepatol. 2023 06 1;:
Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
Kum DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, Verrier ER, Baumert TF, Liu C, Deval J, Corthout N, Munck S, Beigelman L, Blatt LM, Symons JA, Raboisson P, Jekle A, Vendeville S, Debing Y
Hepatology. 2023 04 28;:
Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
Crouchet E, Baumert TF
J Hepatol. 2023 04 21;:
Polymorphisms within DIO2 and GADD45A genes increase the risk of liver disease progression in chronic hepatitis b carriers.
Rybicka M, Verrier ER, Baumert TF, Bielawski KP
Sci Rep. 2023 04 14;13(1):6124
Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.
Jilg N, Baumert TF
Hepatology. 2023 04 11;:
Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
Lucifora J, Alfaiate D, Pons C, Michelet M, Ramirez R, Fusil F, Amirache F, Rossi A, Legrand AF, Charles E, Vegna S, Farhat R, Rivoire M, Passot G, Gadot N, Testoni B, Bach C, Baumert TF, Hyrina A, Beran RK, Zoulim F, Boonstra A, Büning H, Verrier ER, Cosset FL, Fletcher SP, Salvetti A, Durantel D
J Hepatol. 2023 01 23;:
The scientific basis of combination therapy for chronic hepatitis B functional cure.
Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, Maini MK, Terrault NA, Zoulim F
Nat Rev Gastroenterol Hepatol. 2023 01 11;:
Tight Junction Protein Signaling and Cancer Biology.
Nehme Z, Roehlen N, Dhawan P, Baumert TF
Cells. 2023 01 6;12(2):
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Roehlen N, Saviano A, El Saghire H, Crouchet E, Nehme Z, Del Zompo F, Jühling F, Oudot MA, Durand SC, Duong FHT, Cherradi S, Gonzalez Motos V, Almeida N, Ponsolles C, Heydmann L, Ostyn T, Lallement A, Pessaux P, Felli E, Cavalli A, Sgrignani J, Thumann C, Koutsopoulos O, Fuchs BC, Hoshida Y, Hofmann M, Vyberg M, Viuff BM, Galsgaard ED, Elson G, Toso A, Meyer M, Iacone R, Schweighoffer T, Teixeira G, Moll S, De Vito C, Roskams T, Davidson I, Heide D, Heikenwälder M, Zeisel MB, Lupberger J, Mailly L, Schuster C, Baumert TF
Sci Transl Med. 2022 12 21;14(676):eabj4221
Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target.
Verrier ER, Ligat G, Heydmann L, Doernbrack K, Miller J, Maglott-Roth A, Jühling F, El Saghire H, Heuschkel MJ, Fujiwara N, Hsieh SY, Hoshida Y, Root DE, Felli E, Pessaux P, Mukherji A, Mailly L, Schuster C, Brino L, Nassal M, Baumert TF
Gut. 2022 12 9;:
Tumor microenvironment-derived serum markers as a new frontier of diagnostic and prognostic assessment in biliary tract cancers.
Désert R, Giannone F, Schuster C, Baumert TF
Int J Cancer. 2022 12 1;:
A stable hepatitis D virus-producing cell line for host target and drug discovery.
Bach C, Lucifora J, Delphin M, Heydmann L, Heuschkel MJ, Pons C, Goto K, Scheers E, Schuster C, Durantel D, Pauwels F, Baumert TF, Verrier ER
Antiviral Res. 2022 11 26;209:105477
SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
Arandhara VL, Patrick McClure C, Tarr AW, Chappell S, Morgan K, Baumert TF, Irving WL, Ball JK
J Med Virol. 2022 11 22;:
Physiomimetic In Vitro Human Models for Viral Infection in the Liver.
McDuffie DG, Barr DM, Helm MG, Baumert TF, Agarwal A, Thomas E
Semin Liver Dis. 2022 11 19;:
Treatment of HCC with Claudin-1 specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, Cherradi S, Duong FHT, Almeida N, Saviano A, Fernández-Vaquero M, Riedl T, El Saghire H, Durand SC, Ponsolles C, Oudot MA, Martin R, Brignon N, Felli E, Pessaux P, Lallement A, Davidson I, Bandiera S, Thumann C, Marchand P, Moll S, Nicolay B, Bardeesy N, Hoshida Y, Heikenwälder M, Iacone R, Toso A, Meyer M, Elson G, Schweighoffer T, Teixeira G, Zeisel MB, Laquerriere P, Lupberger J, Schuster C, Mailly L, Baumert TF
J Hepatol. 2022 10 26;:
Inhibiting cell-to-cell transmission to reach HDV cure: the importance of IFNα.
Lucifora J, Verrier ER, Baumert TF
J Hepatol. 2022 08 8;:
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.
Crouchet E, Li S, Sojoodi M, Bandiera S, Fujiwara N, El Saghire H, Zhu S, Qian T, Rasha FA, Del Zompo F, Barrett SC, Schaeffer E, Oudot MA, Ponsolles C, Durand SC, Ghoshal S, Arora G, Giannone F, Chung RT, Slovic N, Van Renne N, Felli E, Pessaux P, Lupberger J, Pochet N, Schuster C, Tanabe KK, Hoshida Y, Fuchs BC, Baumert TF
JCI Insight. 2022 07 8;7(13):
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y
Sci Transl Med. 2022 06 22;14(650):eabo4474
Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
Doffoel M, Tripon S, Ernwein F, Chaffraix F, Haumesser L, Bader R, Lang JP, Lang A, Paya D, Royant M, Velay-Rusch A, Tebacher M, Meyer N, Habersetzer F, Baumert T
Eur J Gastroenterol Hepatol. 2022 May 1;34(5):560-566
Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
Deffieu MS, Clément CMH, Dorobantu CM, Partiot E, Bare Y, Faklaris O, Rivière B, Ayala-Nunez NV, Baumert TF, Rondé P, Mély Y, Lucansky V, Gaudin R
Hepatology. 2022 Apr 7;:
Safety and antiviral activity of EGFR inhibition by erlotinib in chronic hepatitis C patients: a phase Ib randomized controlled trial.
Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, Baumert TF
Clin Transl Gastroenterol. 2022 Apr 1;:
Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences.
Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J
Int J Mol Sci. 2022 Mar 3;23(5):
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives.
Taverniti V, Ligat G, Debing Y, Kum DB, Baumert TF, Verrier ER
J Clin Med. 2022 Mar 1;11(5):
Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with Covid-19.
Tripon S, Bilbault P, Fabacher T, Lefebvre N, Lescuyer S, Andres E, Schmitt E, Garnier-Kepka S, Borgne PL, Muller J, Merdji H, Chaffraix F, Mutter D, Baumert TF, Meziani F, Doffoel M
Clin Res Hepatol Gastroenterol. 2022 Feb 25;:101894
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.
Dana J, Venkatasamy A, Saviano A, Lupberger J, Hoshida Y, Vilgrain V, Nahon P, Reinhold C, Gallix B, Baumert TF
Hepatol Int. 2022 Feb 9;:
Hepatitis C treatment in patients with substance use disorder: the faster the better.
Saviano A, Heroin L, Mayer P, Baumert TF
Hepatobiliary Surg Nutr. 2022 Feb;11(1):129-131
Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method.
Verrier ER, Salvetti A, Pons C, Michelet M, Rivoire M, Baumert TF, Durantel D, Lucifora J
Antiviral Res. 2022 Jan 17;198:105250
Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.
Lupberger J, Baumert TF
J Clin Med. 2021 Dec 31;11(1):
Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
Doffoel M, Ernwein F, Chaffraix F, Haumesser L, Tripon S, Bader R, Lang JP, Lang A, Paya D, Royant M, Velay-Rusch A, Tebacher M, Meyer N, Habersetzer F, Baumert T
Eur J Gastroenterol Hepatol. 2021 Dec 30;:
Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development.
Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya AK, Tung MG, Crouchet E, Song WM, Marquez CA, Panda G, Hoshida A, Raman I, Li QZ, Lewis C, Yopp A, Rich NE, Singal AG, Nakagawa S, Goossens N, Higashi T, Koh AP, Bian CB, Hoshida H, Tabrizian P, Gunasekaran G, Florman S, Schwarz ME, Hiotis SP, Nakahara T, Aikata H, Murakami E, Beppu T, Baba H, Warren A, Bhatia S, Kobayashi M, Kumada H, Fobar AJ, Parikh ND, Marrero JA, Rwema SH, Nair V, Patel M, Kim-Schulze S, Corey K, O'Leary JG, Klintmalm GB, Thomas DL, Dibas M, Rodriguez G, Zhang B, Friedman SL, Baumert TF, Fuchs B, Chayama K, Zhu S, Chung RT, Hoshida Y
Gastroenterology. 2021 Dec 21;:
Liver cell circuits and therapeutic discovery for advanced liver disease and cancer.
Crouchet E, Schuster C, Baumert TF
C R Biol. 2021 11 15;344(3):233-248
Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V
J Hepatol. 2021 Oct 19;:
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery.
Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernández-Vaquero M, Riedl T, Sun X, Hirschfield H, Jühling F, Zhu S, Roehlen N, Ponsolles C, Heydmann L, Saviano A, Qian T, Venkatesh A, Lupberger J, Verrier ER, Sojoodi M, Oudot MA, Duong FHT, Masia R, Wei L, Thumann C, Durand SC, González-Motos V, Heide D, Hetzer J, Nakagawa S, Ono A, Song WM, Higashi T, Sanchez R, Kim RS, Bian CB, Kiani K, Croonenborghs T, Subramanian A, Chung RT, Straub BK, Schuppan D, Ankavay M, Cocquerel L, Schaeffer E, Goossens N, Koh AP, Mahajan M, Nair VD, Gunasekaran G, Schwartz ME, Bardeesy N, Shalek AK, Rozenblatt-Rosen O, Regev A, Felli E, Pessaux P, Tanabe KK, Heikenwälder M, Schuster C, Pochet N, Zeisel MB, Fuchs BC, Hoshida Y, Baumert TF
Nat Commun. 2021 Sep 17;12(1):5525
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.
Zhuang X, Tsukuda S, Wrensch F, Wing PA, Schilling M, Harris JM, Borrmann H, Morgan SB, Cane JL, Mailly L, Thakur N, Conceicao C, Sanghani H, Heydmann L, Bach C, Ashton A, Walsh S, Tan TK, Lisa Schimanski, A Huang KY, Schuster C, Watashi K, Hinks TS, Jagannath A, Vausdevan SR, Bailey D, Baumert TF, McKeating JA
iScience. 2021 Sep 16;:103144
Hepatitis B virus compartmentalization and single-cell differentiation in hepatocellular carcinoma.
Jühling F, Saviano A, Ponsolles C, Heydmann L, Crouchet E, Durand SC, El Saghire H, Felli E, Lindner V, Pessaux P, Pochet N, Schuster C, Verrier ER, Baumert TF
Life Sci Alliance. 2021 Sep;4(9):
Differences between sporadic hyperplastic gastric polyps and portal hypertensive gastric polyps: a review.
Héroin L, Saviano A, Fenouil T, Sosa-Valencia L, Baumert TF, Habersetzer F, Mayer P
Eur J Gastroenterol Hepatol. 2021 Aug 23;:
New Insights into Human Cytomegalovirus pUL52 Structure.
Muller C, Alain S, Gourin C, Baumert TF, Ligat G, Hantz S
Viruses. 2021 Aug 18;13(8):
Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection.
Heuschkel MJ, Baumert TF, Verrier ER
Viruses. 2021 Aug 3;13(8):
Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury.
Saviano A, Baumert TF
J Hepatol. 2021 Jul 15;:
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.
Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y
Med (N Y). 2021 Jul 9;2(7):836-850.e10
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression.
Sarkar S, Kemper J, Sarkar R, Brants L, Friebe A, Spengler U, Schläpfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Discher T, Zeuzem S, Berg T, Schaefer M
J Affect Disord. 2021 Jun 23;292:766-772
Laparoscopic anatomical liver resection for malignancies using positive or negative staining technique with intraoperative indocyanine green-fluorescence imaging.
Felli E, Ishizawa T, Cherkaoui Z, Diana M, Tripon S, Baumert TF, Schuster C, Pessaux P
HPB (Oxford). 2021 Jun 7;:
"We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
Baumert TF
J Hepatol. 2021 May 25;:
Hepatitis B virus-host interactions and novel targets for viral cure.
Ligat G, Verrier ER, Nassal M, Baumert TF
Curr Opin Virol. 2021 May 21;49:41-51
Circadian regulation of SARS-CoV-2 infection in lung epithelial cells.
Zhuang X, Tsukuda S, Wrensch F, Wing PA, Borrmann H, Harris JM, Morgan SB, Mailly L, Thakur N, Conceicao C, Sanghani H, Heydmann L, Bach C, Ashton A, Walsh S, Tan TK, Schimanski L, Huang KA, Schuster C, Watashi K, Hinks TS, Jagannath A, Vausdevan SR, Bailey D, Baumert TF, McKeating JA
bioRxiv. 2021 Mar 21;:
Circadian control of hepatitis B virus replication.
Zhuang X, Forde D, Tsukuda S, D'Arienzo V, Mailly L, Harris JM, Wing PAC, Borrmann H, Schilling M, Magri A, Rubio CO, Maidstone RJ, Iqbal M, Garzon M, Minisini R, Pirisi M, Butterworth S, Balfe P, Ray DW, Watashi K, Baumert TF, McKeating JA
Nat Commun. 2021 Mar 12;12(1):1658
Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development.
Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J
J Clin Med. 2021 Mar 2;10(5):
Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses.
Muller C, Alain S, Baumert TF, Ligat G, Hantz S
Life (Basel). 2021 Feb 16;11(2):
Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.
Wing PA, Liu PJ, Harris JM, Magri A, Michler T, Zhuang X, Borrmann H, Minisini R, Frampton NR, Wettengel JM, Mailly L, D'Arienzo V, Riedl T, Nobre L, Weekes MP, Pirisi M, Heikenwalder M, Baumert TF, Hammond EM, Mole DR, Protzer U, Balfe P, McKeating JA
J Hepatol. 2021 Jan 28;:
Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure.
Polyak SJ, Crispe IN, Baumert TF
Pathogens. 2021 Jan 7;10(1):
Liver disease and COVID-19: from Pathogenesis to Clinical Care.
Saviano A, Wrensch F, Ghany MG, Baumert TF
Hepatology. 2020 Dec 17;:
Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.
Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK
J Clin Med. 2020 Nov 25;9(12):
Silencing of the HBV episome through degradation of HBx protein: Towards functional cure?
Lucifora J, Baumert TF
J Hepatol. 2020 Nov 10;:
Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes.
Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP
Cancers (Basel). 2020 Nov 7;12(11):
FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?
Saviano A, Tripon S, Baumert TF
Hepatobiliary Surg Nutr. 2020 Oct;9(5):661-664
Targeting Viral cccDNA for Cure of Chronic Hepatitis B.
Ligat G, Goto K, Verrier E, Baumert TF
Curr Hepatol Rep. 2020 09;19(3):235-244
Roadblocks and fast tracks: How RNA binding proteins affect the viral RNA journey in the cell.
Girardi E, Pfeffer S, Baumert TF, Majzoub K
Semin. Cell Dev. Biol.. 2020 Aug 23;:
Perturbation of the circadian clock and pathogenesis of NAFLD.
Mukherji A, Dachraoui M, Baumert TF
Metab. Clin. Exp.. 2020 Aug 11;:154337
Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.
Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, Chlupac J, Chaperot L, Durand S, Baumert TF, Pichova I, Lubyova B, Hirsch I, Weber J
Sci Rep. 2020 Jul 29;10(1):12767
Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection.
Mayer P, Saviano A, Kassegne L, Baumert TF, Reimund JM, Habersetzer F
Dig Liver Dis. 2020 Jul 27;:
Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
Tripon S, Mayer P, Svab A, Habersetzer F, Pessaux P, Baumert TF, Enescu I
Clin Res Hepatol Gastroenterol. 2020 Jul 9;:
Single-cell genomics and spatial transcriptomics: discovery of novel cell states and cellular interactions in liver physiology and disease biology.
Saviano A, Henderson NC, Baumert TF
J. Hepatol.. 2020 Jun 10;:
A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor.
Eller C, Heydmann L, Colpitts CC, El Saghire H, Piccioni F, Jühling F, Majzoub K, Pons C, Bach C, Lucifora J, Lupberger J, Nassal M, Cowley GS, Fujiwara N, Hsieh SY, Hoshida Y, Felli E, Pessaux P, Sureau C, Schuster C, Root DE, Verrier ER, Baumert TF
Nat Commun. 2020 Jun 1;11(1):2707
Genetic variation in IL-10 influences the progression of hepatitis B infection.
Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP
Int. J. Infect. Dis.. 2020 May 6;:
Imaging-AMARETTO: An Imaging Genomics Software Tool to Interrogate Multiomics Networks for Relevance to Radiography and Histopathology Imaging Biomarkers of Clinical Outcomes.
Gevaert O, Nabian M, Bakr S, Everaert C, Shinde J, Manukyan A, Liefeld T, Tabor T, Xu J, Lupberger J, Haas BJ, Baumert TF, Hernaez M, Reich M, Quintana FJ, Uhlmann EJ, Krichevsky AM, Mesirov JP, Carey V, Pochet N
JCO Clin Cancer Inform. 2020 May;4:421-435
Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip.
Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J
Int J Mol Sci. 2020 Apr 26;21(9):
Hepatitis C virus infection and tight junction proteins: The ties that bind.
Mailly L, Baumert TF
Biochim Biophys Acta Biomembr. 2020 Apr 5;:183296
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.
Roehlen N, Crouchet E, Baumert TF
Cells. 2020 Apr 3;9(4):
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF
Gut. 2020 Mar 26;:
Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
Felli E, Baumert T, Pessaux P
Clin Res Hepatol Gastroenterol. 2020 Mar 18;:
Characterization of endogenous Claudin1 expression, motility and susceptibility to Hepatitis C Virus in CRISPR knock-in cells.
Clément CMH, Deffieu MS, Dorobantu CM, Baumert TF, Ayala-Nunez NV, Mély Y, Ronde P, Gaudin R
Biol. Cell. 2020 Feb 7;:
Tight Junction Proteins and the Biology of Hepatobiliary Disease.
Roehlen N, Roca Suarez AA, El Saghire H, Saviano A, Schuster C, Lupberger J, Baumert TF
Int J Mol Sci. 2020 Jan 28;21(3):
Targeting the Host for New Therapeutic Perspectives in Hepatitis D.
Turon-Lagot V, Saviano A, Schuster C, Baumert TF, Verrier ER
J Clin Med. 2020 Jan 14;9(1):
Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease.
Roca Suarez AA, Testoni B, Baumert TF, Lupberger J
Front Immunol. 2020 ;11:624034
Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM
J. Hepatol.. 2019 Dec 18;:
Follicular T helper cells shape the HCV-specific CD4 T cell repertoire after viral elimination.
Smits M, Zoldan K, Ishaque N, Gu Z, Jechow K, Wieland D, Conrad C, Eils R, Fauvelle C, Baumert TF, Emmerich F, Bengsch B, Neumann-Haefelin C, Hofmann M, Thimme R, Boettler T
J. Clin. Invest.. 2019 Nov 7;:
Hepatitis D Virus Infection Revisited.
Verrier ER, Majzoub K, Baumert TF
Gastroenterology. 2019 Oct 3;:
Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
Virzì A, Suarez AAR, Baumert TF, Lupberger J
Cold Spring Harb Perspect Med. 2019 Sep 9;:
Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance.
Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D'Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M
Hepatol Commun. 2019 Sep;3(9):1205-1220
Radiomics in hepatocellular carcinoma: a quantitative review.
Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B
Hepatol Int. 2019 Aug 31;:
A recombinant HCV genotype 1a E1/E2 envelope glycoprotein vaccine elicits antibodies that differentially neutralize closely related 2a strains through interactions of the N-terminal hypervariable region 1 of E2 with scavenger receptor B1.
Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M
J. Virol.. 2019 Aug 28;:
The Innate Antiviral Response in Animals: An Evolutionary Perspective from Flagellates to Humans.
Majzoub K, Wrensch F, Baumert TF
Viruses. 2019 Aug 16;11(8):
Uncovering the mechanism of action of aspirin in HCC chemoprevention.
Roehlen N, Baumert TF
EBioMedicine. 2019 Aug 6;:
A human liver cell atlas reveals heterogeneity and epithelial progenitors.
Aizarani N, Saviano A, Sagar, Mailly L, Durand S, Herman JS, Pessaux P, Baumert TF, Grün D
Nature. 2019 Jul 10;:
Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C.
Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J
J. Infect. Dis.. 2019 Jun 4;:
Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease.
Saviano A, Baumert TF
Hepatobiliary Surg Nutr. 2019 Jun;8(3):307-310
Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma.
Bou About G, Thiebault E, Wattenhofer-Donzé M, Jacobs H, Guimond A, Sorg T, Robinet E, Baumert TF, Monassier L, Herault Y
Curr Protoc Mouse Biol. 2019 May 30;:e62
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH
PLoS Pathog.. 2019 May 17;15(5):e1007772
Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma.
Baumert TF, Hoshida Y
Viruses. 2019 May 15;11(5):
Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
Herzog K, Bandiera S, Pernot S, Fauvelle C, Jühling F, Weiss A, Bull A, Durand SC, Chane-Woon-Ming B, Pfeffer S, Mercey M, Lerat H, Meunier JC, Raffelsberger W, Brino L, Baumert TF, Zeisel MB
Gut. 2019 May 10;:
IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.
Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF
Hepatology. 2019 May 7;:
Learning from a clinical cohort for HCV vaccine development.
Wrensch F, Keck ZY, Foung SKH, Baumert TF
J. Hepatol.. 2019 Apr 13;:
Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development.
Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF
Gastroenterology. 2019 Apr 9;:
The Circadian Clock and Liver Function in Health and Disease.
Mukherji A, Bailey SM, Staels B, Baumert TF
J. Hepatol.. 2019 Mar 28;:
Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response.
Schwenzer H, Jühling F, Chu A, Pallett LJ, Baumert TF, Maini M, Fassati A
Cell Rep. 2019 Mar 19;26(12):3416-3428.e5
Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF
Gut. 2019 Mar 4;:
HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF
Gastroenterology. 2019 Mar 2;:
The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication.
Zhuang X, Magri A, Hill M, Lai AG, Kumar A, Rambhatla SB, Donald CL, Lopez-Clavijo AF, Rudge S, Pinnick K, Chang WH, Wing PAC, Brown R, Qin X, Simmonds P, Baumert TF, Ray D, Loudon A, Balfe P, Wakelam M, Butterworth S, Kohl A, Jopling CL, Zitzmann N, McKeating JA
Nat Commun. 2019 Jan 22;10(1):377
An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion.
Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen YM, Wang YX
Antiviral Res.. 2018 Dec 29;:
In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF
Antiviral Res.. 2018 Dec 29;:
Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.
Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM
Gut. 2018 Dec 22;:
The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses.
Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF
Cell. Mol. Life Sci.. 2018 Nov;75(21):3895-3905
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC
J. Gastrointest. Surg.. 2018 Oct 26;:
Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
Baumert TF, Berg T, Lim JK, Nelson DR
Gastroenterology. 2018 Oct 17;:
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.
Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M
J. Virol.. 2018 Oct 15;92(20):
Tight junction proteins in gastrointestinal and liver disease.
Zeisel MB, Dhawan P, Baumert TF
Gut. 2018 Oct 8;:
Oncogenic Signaling Induced by HCV Infection.
Virzì A, Roca Suarez AA, Baumert TF, Lupberger J
Viruses. 2018 Oct 2;10(10):
Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
Roca Suarez AA, Baumert TF, Lupberger J
J. Hepatol.. 2018 Jun 21;:
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L, Song OR, Prentoe J, Helle F, L'homme L, Gattolliat CH, Vandeputte A, Fénéant L, Belouzard S, Baumert TF, Asselah T, Bukh J, Brodin P, Cocquerel L, Rouillé Y, Dubuisson J
J. Virol.. 2018 05 15;92(10):
HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R
Gastroenterology. 2018 05;154(6):1791-1804.e22
Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF
Hepatology. 2018 Apr 20;:
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.
Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T
Virus Res.. 2018 03 15;248:53-62
A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.
Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D
PLoS Pathog.. 2018 03;14(3):e1006908
Viral manipulation of STAT3: Evade, exploit, and injure.
Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J
PLoS Pathog.. 2018 Mar;14(3):e1006839
Solute carrier NTCP, a key actor in liver infections by hepatitis viruses and a promising antiviral target.
Verrier ER, Heydmann L, Baumert TF, Schuster C
Virologie (Montrouge). 2018 Feb 1;22(1):55-66
Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine.
Foung SKH, Baumert TF
Front Immunol. 2018 ;9:2577
Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.
Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF
Front Immunol. 2018 ;9:1436
Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF
Therap Adv Gastroenterol. 2018 ;11:1756284818759483
Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.
Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung SKH
Front Immunol. 2018 ;9:1194
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P
Antiviral Res.. 2017 Dec;148:53-64
Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8 T Cells in Chronic versus Acute Infection.
Wolski D, Foote PK, Chen DY, Lewis-Ximenez LL, Fauvelle C, Aneja J, Walker A, Tonnerre P, Torres-Cornejo A, Kvistad D, Imam S, Waring MT, Tully DC, Allen TM, Chung RT, Timm J, Haining WN, Kim AY, Baumert TF, Lauer GM
Immunity. 2017 10 17;47(4):648-663.e8
Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
Colpitts CC, Chung RT, Baumert TF
ACS Infect Dis. 2017 09 8;3(9):620-623
A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.
Fauvelle C, Lambotin M, Heydmann L, Prakash E, Bhaskaran S, Vishwaraman M, Baumert TF, Moog C
Hepatol Int. 2017 Sep;11(5):440-445
Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector.
Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F, Inchauspé A, Michelet M, Michel ML, Levrero M, Cortez P, Baumert TF, Cosset FL, Challier C, Zoulim F, Durantel D
Antiviral Res.. 2017 Sep;145:14-19
Toward novel immunocompetent animal models for hepatitis B virus infection.
Mailly L, Zeisel MB, Baumert TF
Hepatology. 2017 09;66(3):691-693
SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
Colpitts CC, Baumert TF
J. Hepatol.. 2017 Aug;67(2):211-213
Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.
Crouchet E, Baumert TF, Schuster C
Expert Rev Proteomics. 2017 07;14(7):593-606
Protein kinase D at the Golgi controls NLRP3 inflammasome activation.
Zhang Z, Meszaros G, He WT, Xu Y, de Fatima Magliarelli H, Mailly L, Mihlan M, Liu Y, Puig Gámez M, Goginashvili A, Pasquier A, Bielska O, Neven B, Quartier P, Aebersold R, Baumert TF, Georgel P, Han J, Ricci R
J. Exp. Med.. 2017 Jul;:
P36 determines host cell receptor usage during sporozoite invasion.
Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O
Elife. 2017 05 16;6:
Signalome-wide assessment of host cell response to hepatitis C virus.
Haqshenas G, Wu J, Simpson KJ, Daly RJ, Netter HJ, Baumert TF, Doerig C
Nat Commun. 2017 May 8;8:15158
Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJO, McKeating JA
J. Hepatol.. 2017 05;66(5):919-929
Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C
Gut. 2017 05;66(5):896-907
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
Haddad JG, Rouillé Y, Hanoulle X, Descamps V, Hamze M, Dabboussi F, Baumert TF, Duverlie G, Lavie M, Dubuisson J
J. Virol.. 2017 04 15;91(8):
Advancing hepatitis B virus entry inhibitors.
Verrier ER, Schuster C, Baumert TF
J. Hepatol.. 2017 04;66(4):677-679
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
Baumert TF, Jühling F, Ono A, Hoshida Y
BMC Med. 2017 03 14;15(1):52
Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF
Gut. 2017 Mar;:
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ
Antiviral Res.. 2017 Mar;139:129-137
Clinical development of hepatitis C virus host-targeting agents.
Zeisel MB, Baumert TF
Lancet. 2017 02 18;389(10070):674-675
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J
Gut. 2017 Feb;:
Composite vector formulation for multiple siRNA delivery as a host targeting antiviral in a cell culture model of hepatitis C virus (HCV) infection.
Crouchet E, Saad R, Affolter-Zbaraszczuk C, Ogier J, Baumert TF, Schuster C, Meyer F
J Mater Chem B. 2017 Jan 28;5(4):858-865
Claudins in viral infection: from entry to spread.
Colpitts CC, Baumert TF
Pflugers Arch.. 2017 01;469(1):27-34
SMAD About Hepatitis C Virus Cell Entry and Liver Disease.
Colpitts CC, Baumert TF
Gastroenterology. 2017 01;152(1):21-23
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.
Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y,
Cancer Cell. 2016 Dec 12;30(6):879-890
Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.
Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK
Hepatology. 2016 12;64(6):1922-1933
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF
Expert Rev Vaccines. 2016 12;15(12):1535-1544
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P
Gut. 2016 Dec;65(12):2029-2034
Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.
Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SKH
Proc. Natl. Acad. Sci. U.S.A.. 2016 Nov 8;113(45):E6946-E6954
Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF
Hepatology. 2016 Nov;64(5):1495-1506
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.
Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB
Curr Opin Virol. 2016 10;20:99-105
Editorial overview: Viral resistance and challenges for antiviral therapies and vaccines.
Baumert TF, Schuster C
Curr Opin Virol. 2016 10;20:vi-vii
Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.
Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E
Sci Rep. 2016 Oct;6:35230
Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.
Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF
Cell Rep. 2016 Oct;17(5):1357-1368
Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection.
Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF
Viruses. 2016 Sep 20;8(9):
Hepatitis B virus: is a cure possible?
Zeisel MB, Baumert TF
Expert Rev Clin Pharmacol. 2016 Sep;9(9):1129-30
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
Colpitts CC, Baumert TF
Hepatol Int. 2016 Sep;10(5):741-8
Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC, Baumert TF
Viruses. 2016 08 16;8(8):
Translation and protein expression of lncRNAs: Impact for liver disease and hepatocellular carcinoma.
Zeisel MB, Baumert TF
Hepatology. 2016 08;64(2):671-4
Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis.
Moenne-Loccoz R, Severac F, Baumert TF, Habersetzer F
J. Hepatol.. 2016 Aug;65(2):444-6
Hepatitis B virus receptors and molecular drug targets.
Verrier ER, Colpitts CC, Sureau C, Baumert TF
Hepatol Int. 2016 Jul;10(4):567-73
Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.
Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB
J. Virol.. 2016 Jul;90(14):6387-400
Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.
Colpitts CC, Lupberger J, Baumert TF
Proc. Natl. Acad. Sci. U.S.A.. 2016 Jul;113(27):7298-300
Circulating microRNAs for early detection of hepatitis B-related hepatocellular carcinoma.
Bandiera S, Baumert TF, Zeisel MB
Hepatobiliary Surg Nutr. 2016 Jun;5(3):198-200
Management of large hepatocellular carcinoma by sequential transarterial chemoembolization and portal vein embolization: a systematic review of the literature.
Piardi T, Memeo R, Renard Y, Ammendola M, Bruno O, Habersetzer F, Baumert T, Pessaux P, Sommacale D
Minerva Chir. 2016 Jun;71(3):192-200
New perspectives for preventing hepatitis C virus liver graft infection.
Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF
Lancet Infect Dis. 2016 06;16(6):735-745
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses.
Baumert TF, Schuster C, Cosset FL, Dubuisson J, Hofmann M, Tautz N, Zeisel MB, Thimme R
J. Hepatol.. 2016 Apr;64(4):968-73
Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P
Hepatology. 2016 Apr;63(4):1120-34
[Locked outside: cure of chronic hepatitis C using an entry inhibitor].
Mailly L, Zeisel MB, Baumert TF
Med Sci (Paris). 2015 Dec;31(12):1075-7
Use of a Closed Culture System to Improve the Safety of Lentiviral Vector Production.
Wu T, Bour G, Durand S, Lindner V, Gosse F, Zona L, Certoux JM, Diana M, Baumert TF, Marescaux J, Mutter D, Pessaux P, Robinet E
Hum Gene Ther Methods. 2015 Nov 10.
Viral hepatitis: A new HCV cell culture model for the next clinical challenges.
Colpitts CC, Baumert TF
Nat Rev Gastroenterol Hepatol. 2015 Nov;12(11):611-3
Virus-specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-helper Cells in Patients With Acute and Chronic HCV Infections.
Raziorrouh B, Sacher K, Tawar RG, Emmerich F, Neumann-Haefelin C, Baumert TF, Thimme R, Boettler T
Gastroenterology. 2015 Nov 13. pii: S0016-5085(15)01622-4
Host cell kinases and the hepatitis C virus life cycle.
Colpitts CC, Lupberger J, Doerig C, Baumert TF
Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1657-62
Lentiviral hepatitis B pseudotype entry requires NTCP and additional hepatocyte-specific factors.
Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, van de Graaf KF, Protzer U, McKeating JA
J Gen Virol. 2015 Oct 16
Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections.
Colpitts CC, Verrier ER, Baumert TF
ACS Infect Dis. 2015 Sep 11;1(9):420-7
Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF
Hepatology. 2015 Sep;62(3):726-36
Apolipoprotein E Mediates Evasion From Hepatitis C Virus-Neutralizing Antibodies.
Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefevre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF
Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01358-X
High-throughput approaches to unravel hepatitis C virus-host interactions.
Colpitts CC, El-Saghire H, Pochet N, Schuster C, Baumert TF
Virus Res. 2015 Sep 26. pii: S0168-1702(15)30069-1
Retinoic acid-inducible gene 1 and sensing of hepatitis B virus revisited.
Verrier ER, Wieland S, Baumert TF
Hepatology. 2015 Sep;62(3):970-2
Host-targeting agents for treatment of hepatitis B virus infection.
Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB
Curr Opin Virol. 2015 Aug 8;14:41-46
Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry.
Gerold G, Meissner F, Bruening J, Welsch K, Perin PM, Baumert TF, Vondran FW, Kaderali L, Marcotrigiano J, Khan AG, Mann M, Rice CM, Pietschmann T
Cell Rep. 2015 Aug 4;12(5):864-78
A targeted functional RNAi screen uncovers Glypican 5 as an entry factor for hepatitis B and D viruses.
Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoude G, Lopez Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF
Hepatology. 2015 Jul 29
Functional and Biochemical Characterization of HCV Particles Produced in a Humanized Liver Mouse Model.
Calattini S, Fusil F, Mancip J, Dao Thi VL, Granier C, Gadot N, Scoazec JY, Zeisel M, Baumert TF, Lavillette D, Dreux M, Cosset FL
J Biol Chem. 2015 Jul 29. pii: jbc.M115.662999.
Hepatitis C virus infection of cholangiocarcinoma cell lines.
Fletcher NF, Humphreys E, Jennings E, Osburn W, Lissauer S, Wilson GK, van IJzendoorn SC, Baumert TF, Balfe P, Afford S, McKeating JA
J Gen Virol. 2015 Jun;96(Pt 6):1380-8
New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore Monensin A.
Feneant L, Potel J, Francois C, Sane F, Douam F, Belouzard S, Calland N, Vausselin T, Rouille Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L
J Virol. 2015 Jun 3. pii: JVI.00192-15.
Claudins and pathogenesis of viral infection.
Tawar RG, Colpitts CC, Lupberger J, El-Saghire H, Zeisel MB, Baumert TF
Semin Cell Dev Biol. 2015 May 7. pii: S1084-9521(15)00097-X
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londono MC, Habersetzer F
Hepatology. 2015 May;61(5):1485-94
Trans-thoracic minimally invasive liver resection guided by augmented reality.
Hallet J, Soler L, Diana M, Mutter D, Baumert TF, Habersetzer F, Marescaux J, Pessaux P
J Am Coll Surg. 2015 May;220(5):e55-60
[From fly to man: RACK1, an essential actor of the dependent viral translation of IRES].
Hafirassou ML, Meignin C, Baumert T, Schuster C
Med Sci (Paris). 2015 May;31(5):469-72
When one receptor closes, another opens: Claudins and the hepatitis C virus E1 glycoprotein.
Colpitts CC, Zeisel MB, Baumert TF
Hepatology. 2015 Apr 30
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FH, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF
Nat Biotechnol. 2015 Mar 23
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoel M, Leyssen P, Neyts J, Zeisel MB, Baumert TF
Gut. 2015 Mar;64(3):483-94
miR-122--a key factor and therapeutic target in liver disease.
Bandiera S, Pfeffer S, Baumert TF, Zeisel MB
J Hepatol. 2015 Feb;62(2):448-57
Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.
Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bole-Richard E, Deschamps M, Ferrand C, Tiberghien P, Pessaux P, Baumert TF, Robinet E
Gene Ther. 2015 Feb;22(2):172-80
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.
Zeisel MB, Crouchet E, Baumert TF, Schuster C
Viruses. 2015 Nov 2;7(11):5659-85
Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.
Habersetzer F, Moenne-Loccoz R, Meyer N, Schvoerer E, Simo-Noumbissie P, Dritsas S, Baumert TF, Doffoël M
Liver Int.. 2015 Jan;35(1):130-9
PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation.
Lupberger J, Casanova C, Fischer B, Weiss A, Fofana I, Fontaine N, Fujiwara T, Renaud M, Kopp A, Schuster C, Brino L, Baumert TF, Thoma C
Sci Rep. 2015 Sep 1;5:13344
New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology.
Felmlee DJ, Schuster C, Baumert TF
Hepatology. 2014 Dec;60(6):1806-8
A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.
Baumert TF, Fauvelle C, Chen DY, Lauer GM
J Hepatol. 2014 Nov;61(1 Suppl):S34-44
Overcoming the roadblocks in hepatitis C virus infection.
Baumert TF, Zeuzem S
J Hepatol. 2014 Nov;61(1 Suppl):S1-2
RACK1 controls IRES-mediated translation of viruses.
Majzoub K, Hafirassou ML, Meignin C, Goto A, Marzi S, Fedorova A, Verdier Y, Vinh J, Hoffmann JA, Martin F, Baumert TF, Schuster C, Imler JL
Cell. 2014 Nov 20;159(5):1086-95
Templated assembly of albumin-based nanoparticles for simultaneous gene silencing and magnetic resonance imaging.
Mertz D, Affolter-Zbaraszczuk C, Barthes J, Cui J, Caruso F, Baumert TF, Voegel JC, Ogier J, Meyer F
Nanoscale. 2014 Oct 21;6(20):11676-80
Cyclic guanosine monophosphate/adenosine monophosphate synthase (cGAS), innate immune responses, and viral hepatitis.
Verrier ER, Gack MU, Baumert TF
Hepatology. 2014 Sep;60(3):1098-100
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Xiao F, Fofana I, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoel M, Bukh J, Patel AH, Zeisel MB, Baumert TF
PLoS Pathog. 2014 May 15;10(5):e1004128
Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir.
Carbajo-Lozoya J, Ma-Lauer Y, Malesevic M, Theuerkorn M, Kahlert V, Prell E, von Brunn B, Muth D, Baumert TF, Drosten C, Fischer G, von Brunn A
Virus Res. 2014 May 12;184:44-53
IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies.
Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH
J Exp Med. 2014 May 5;211(5):857-68
Curing chronic hepatitis C--the arc of a medical triumph.
Chung RT, Baumert TF
N Engl J Med. 2014 Apr 24;370(17):1576-8
Entry inhibitors and future treatment of hepatitis C.
Fofana I, Jilg N, Chung RT, Baumert TF
Antiviral Res. 2014 Apr;104:136-42
Laparoscopic resection for hepatocellular carcinoma: comparison between Middle Eastern and Western experience.
Piardi T, Sommacale D, Baumert T, Mutter D, Marescaux J, Pessaux P
Hepatobiliary Surg Nutr. 2014 Apr;3(2):60-72
Unraveling hepatitis C virus structure.
Fauvelle C, Felmlee DJ, Baumert TF
Cell Res. 2014 Apr;24(4):385-6
[Hepatitis B and C: from molecular virology to new antiviral therapies (part 2)].
Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D
Dtsch Med Wochenschr. 2014 Apr;139(15):778-82
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D
Hepatology. 2014 Mar;59(3):776-88
Genetically humanized mice recapitulate the entire hepatitis C virus life cycle.
Mailly L, Zeisel MB, Baumert TF
J Hepatol. 2014 Mar;60(3):671-3
In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.
Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E
Mol Ther. 2014 Mar;22(3):634-44
[Hepatitis B and C: From molecular virology to new antiviral therapies (part 1)].
Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D
Dtsch Med Wochenschr. 2014 Mar;139(13):655-9
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.
Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF
Viruses. 2014 Feb 18;6(2):875-92
Host genetics predict clinical deterioration in HCV-related cirrhosis.
King LY, Johnson KB, Zheng H, Wei L, Gudewicz T, Hoshida Y, Corey KE, Ajayi T, Ufere N, Baumert TF, Chan AT, Tanabe KK, Fuchs BC, Chung RT
PLoS One. 2014 Dec 12;9(12):e114747
Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E.
Lefevre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C
PLoS One. 2014 Apr 21;9(4):e95550
Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
Anjum S, Wahid A, Afzal MS, Albecka A, Alsaleh K, Ahmad T, Baumert TF, Wychowski C, Qadri I, Penin F, Dubuisson J
J Infect Dis. 2013 Dec 1;208(11):1888-97
Hepatitis C virus co-opts innate immunity component for lipid droplet formation.
Felmlee DJ, Baumert TF
J Hepatol. 2013 Nov;59(5):1118-20
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF
Hepatology. 2013 Oct;58(4):1225-35
Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
Felmlee DJ, Xiao F, Baumert TF
Hepatology. 2013 Oct;58(4):1203-6
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.
Fofana I, Zona L, Thumann C, Heydmann L, Durand SC, Lupberger J, Blum HE, Pessaux P, Gondeau C, Reynolds GM, McKeating JA, Grunert F, Thompson J, Zeisel MB, Baumert TF
J Virol. 2013 Sep;87(18):10405-10
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.
Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13109-13
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry.
Potel J, Rassam P, Montpellier C, Kaestner L, Werkmeister E, Tews BA, Couturier C, Popescu CI, Baumert TF, Rubinstein E, Dubuisson J, Milhiet PE, Cocquerel L
Cell Microbiol. 2013 Jul;15(7):1234-52
Interferon-lambda polymorphisms and hepatitis C virus clearance revisited.
Lupberger J, Felmlee DJ, Baumert TF
Hepatology. 2013 Jul;58(1):439-41
Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection.
Habersetzer F, Leboeuf C, Doffoel M, Zeisel MB, Baumert TF
Expert Opin Investig Drugs. 2013 Jul;22(7):853-62
A bile acid transporter as a candidate receptor for hepatitis B and D virus entry.
Xiao F, McKeating JA, Baumert TF
J Hepatol. 2013 Jun;58(6):1246-8
TIP47 plays a crucial role in the life cycle of hepatitis C virus.
Ploen D, Hafirassou ML, Himmelsbach K, Sauter D, Biniossek ML, Weiss TS, Baumert TF, Schuster C, Hildt E
J Hepatol. 2013 Jun;58(6):1081-8
Hepatitis C virus vaccines--progress and perspectives.
Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S
Microb Pathog. 2013 May;58:66-72
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.
Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C
Viruses. 2013 May 23;5(5):1292-324
miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo.
Zeisel MB, Pfeffer S, Baumert TF
J Hepatol. 2013 Apr;58(4):821-3
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.
Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A, Florentin J, Tawar RG, Xiao F, Turek M, Durand SC, Duong FH, Heim MH, Cosset FL, Hirsch I, Samuel D, Brino L, Zeisel MB, Le Naour F, McKeating JA, Baumert TF
Cell Host Microbe. 2013 Mar 13;13(3):302-13
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.
Zeisel MB, Lupberger J, Fofana I, Baumert TF
J Hepatol. 2013 Feb;58(2):375-84
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.
Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB
Hepatology. 2013 Feb;57(2):492-504
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I, Xiao F, Thumann C, Turek M, Zona L, Tawar RG, Grunert F, Thompson J, Zeisel MB, Baumert TF
PLoS One. 2013 May 21;8(5):e64221
Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.
Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoel M, Gut JP, Fofana I, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E
PLoS One. 2013 Jun 20;8(6):e67254
Hepatitis C virus entry.
Zeisel MB, Felmlee DJ, Baumert TF
Curr Top Microbiol Immunol. 2013;369:87-112
Hepatitis C virus infection and related liver disease: the quest for the best animal model.
Mailly L, Robinet E, Meuleman P, Baumert TF, Zeisel MB
Front Microbiol. 2013 Jul 26;4:213
Potent calcium phosphate nanoparticle surface coating for in vitro and in vivo siRNA delivery: a step toward multifunctional nanovectors.
Devarasu T, Saad R, Ouadi A, Frisch B, Robinet E, Laquerriere P, Voegel JC, Baumert T, Ogier J, Meyer F
J Mat Chem B. 2013;1(36):4692-700.
HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells.
Florentin J, Aouar B, Dental C, Thumann C, Firaguay G, Gondois-Rey F, Soumelis V, Baumert TF, Nunes JA, Olive D, Hirsch I, Stranska R
Blood. 2012 Nov 29;120(23):4544-51
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells.
Da Costa D, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB, Baumert TF
J Virol. 2012 Nov;86(21):11919-25
Neutralizing antibodies and pathogenesis of hepatitis C virus infection.
Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF
Viruses. 2012 Oct 9;4(10):2016-30
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion.
Guan M, Wang WB, Liu XQ, Tong YM, Liu Y, Ren H, Zhu SY, Dubuisson J, Baumert TF, Zhu YZ, Peng HR, Aurelian L, Zhao P, Qi ZT
J Biol Chem. 2012 Oct 12;287(42):35631-45
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.
Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M
J Biol Chem. 2012 Sep 7;287(37):31242-57
Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH
Gastroenterology. 2012 Sep;143(3):777-86.e1-6
Cholesterol uptake and hepatitis C virus entry.
Lupberger J, Felmlee DJ, Baumert TF
J Hepatol. 2012 Jul;57(1):215-7
Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T
Ann Intern Med. 2012 Jul 17;157(2):94-103.
Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential.
Jo J, Bengsch B, Seigel B, Rau SJ, Schmidt J, Bisse E, Aichele P, Aichele U, Joeckel L, Royer C, Sa Ferreira K, Borner C, Baumert TF, Blum HE, Lohmann V, Fischer R, Thimme R
J Hepatol. 2012 Jul;57(1):9-16
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.
Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoel M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF
Gastroenterology. 2012 Jul;143(1):223-233.e9
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A
J Hepatol. 2012 Jul;57(1):17-23
A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses.
Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U
J Infect Dis. 2012 Jun;205(11):1654-64
Hepatitis C virus induces CD81 and claudin-1 endocytosis.
Farquhar MJ, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert TF, Rappoport JZ, Balfe P, McKeating JA
J Virol. 2012 Apr;86(8):4305-16
Hepatitis C virus infects the endothelial cells of the blood-brain barrier.
Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA
Gastroenterology. 2012 Mar;142(3):634-643.e6
Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle.
Molina-Jimenez F, Benedicto I, Dao Thi VL, Gondar V, Lavillette D, Marin JJ, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano PL
Virology. 2012 Mar 30;425(1):31-9
A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses.
Polyak SJ, Morishima C, Scott JD, Gastaminza P, Cox A, de Araujo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr
Gastroenterology. 2012 Jan;142(1):e1-5.
Boceprevir and personalized medicine in hepatitis C virus infection.
Habersetzer F, Leboeuf C, Doffoel M, Baumert TF
Pharmgenomics Pers Med. 2012;5:125-37
Hepatitis C virus fails to activate NF-kappaB signaling in plasmacytoid dendritic cells.
Dental C, Florentin J, Aouar B, Gondois-Rey F, Durantel D, Baumert TF, Nunes JA, Olive D, Hirsch I, Stranska R
J Virol. 2012 Jan;86(2):1090-6
Opening the door for hepatitis C virus infection in genetically humanized mice.
Zeisel MB, Da Costa D, Baumert TF
Hepatology. 2011 Nov;54(5):1873-5
[Open Sesame: regulation of hepatitis C virus entry into hepatocytes].
Turek M, Lupberger J, Baumert TF, Zeisel MB
Med Sci (Paris). 2011 Nov;27(11):929-31
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ
Hepatology. 2011 Oct;54(4):1135-48
A first step towards a mouse model for hepatitis C virus infection containing a human immune system.
Robinet E, Baumert TF
J Hepatol. 2011 Sep;55(3):718-20
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.
Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Trepo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspe G
Gastroenterology. 2011 Sep;141(3):890-899.e1-4
Hepatitis C virus and neutralizing antibodies.
Fauvelle C, Heydmann L, Zeisel MB, Baumert TF, Stoll-Keller F, Fafi-Kremer S
. 2011 Sep-oct;15(5):326-36.
Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies.
Ehrhardt M, Leidinger P, Keller A, Baumert T, Diez J, Meese E, Meyerhans A
Hepatology. 2011 Sep 2;54(3):1112-3
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF
Nat Med. 2011 May;17(5):589-95
Triglyceride synthesis and hepatitis C virus production: identification of a novel host factor as antiviral target.
Schuster C, Lefevre M, Baumert TF
Hepatology. 2011 Mar;53(3):1046-8
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA
J Virol. 2011 Jan;85(1):596-605
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.
Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F
J Hepatol. 2011 Jan;54(1):48-55
Hepatitis C virus entry and glucocorticosteroids.
Fafi-Kremer S, Habersetzer F, Baumert TF
J Hepatol. 2010 Dec;53(6):1148-50
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms.
Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K
J Virol. 2010 Nov;84(22):12048-57
Hepatitis C virus infection of neuroepithelioma cell lines.
Fletcher NF, Yang JP, Farquhar MJ, Hu K, Davis C, He Q, Dowd K, Ray SC, Krieger SE, Neyts J, Baumert TF, Balfe P, McKeating JA, Wong-Staal F
Gastroenterology. 2010 Oct;139(4):1365-74
Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells.
Lambotin M, Baumert TF, Barth H
J Virol. 2010 Sep;84(17):8964-9
Host and viral determinants for engraftment of virus permissive human hepatocytes into chimeric immunodeficient mice.
Robinet E, Baumert TF
J Hepatol. 2010 Sep;53(3):421-3
Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection.
Pfeffer S, Baumert TF
Gastroenterol Clin Biol. 2010 Sep;34(8-9):431-5
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF
Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4
Getting closer to the patient: upgrade of hepatitis C virus infection in primary human hepatocytes.
Zeisel MB, Turek M, Baumert TF
J Hepatol. 2010 Aug;53(2):388-9
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.
Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoel M, Wolf P, Stoll-Keller F, Baumert TF
J Exp Med. 2010 Aug 30;207(9):2019-31
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.
Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, Rychlowska M, Foung SK, Baumert TF, Angus AG, Patel AH
J Virol. 2010 Jun;84(11):5494-507
Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.
Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF
Trends Mol Med. 2010 Jun;16(6):277-86
A look behind closed doors: interaction of persistent viruses with dendritic cells.
Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H
Nat Rev Microbiol. 2010 May;8(5):350-60
Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD
Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E
Curr Opin Investig Drugs. 2010 May;11(5):559-70.
Antagonizing microRNA-122 and treatment of hepatitis C virus infection.
Pfeffer S, Baumert TF
Hepatology. 2010 Apr;51(4):1461-3.
[Tropism of hepatitis C virus for leukocytes-- importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing]
Moenne-Loccoz R, Razafinjatovo C, Habersetzer F, Ananna A, Doffoel M, Wolf P, Gut JP, Baumert T, Stoll-Keller F, Schvoerer E
Pathol Biol (Paris). 2010 Apr;58(2):170-4
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T
PLoS Pathog. 2010 Jul 1;6:e1000978.
Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles.
Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C
Hepatology. 2010 Jan;51(1):43-53.
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E
Gut. 2009 Dec;58(12):1644-53
Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA
J Viral Hepat. 2009 Oct;16(10):732-7
Adaptive Immunity to Hepatitis C Virus
Zeisel MB, Fafi-Kremer S, Robinet E, Habersetzer F, Baumert TF, Stoll-Keller F
Viruses-basel. 2009 Sep;1(2):276-97
Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver.
Pfeffer S, Baumert TF
J Hepatol. 2009 Sep;51(3):606-9
GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.
Habersetzer F, Baumert TF, Stoll-Keller F
Curr Opin Mol Ther. 2009 Aug;11(4):456-62.
Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells.
Sava IG, Zhang F, Toma I, Theilacker C, Li B, Baumert TF, Holst O, Linhardt RJ, Huebner J
J Biol Chem. 2009 Jul 3;284(27):18194-201
HCV entry and neutralizing antibodies: lessons from viral variants.
Zeisel MB, Baumert TF
Future Microbiol. 2009 Jun;4:511-7.
Closing the gap: the tight junction protein occludin and hepatitis C virus entry.
Eyre NS, Baumert TF, Beard MR
Hepatology. 2009 May;49(5):1770-2.
Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability.
Weseslindtner L, Neumann-Haefelin C, Viazov S, Haberstroh A, Kletzmayr J, Aberle JH, Timm J, Ross SR, Klauser-Braun R, Baumert TF, Roggendorf M, Thimme R, Holzmann H
J Hepatol. 2009 Apr;50(4):693-704
Rapid synchronization of hepatitis C virus infection by magnetic adsorption.
Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH
J Virol Methods. 2009 Apr;157(1):69-79
Development of hepatitis C virus vaccines: challenges and progress.
Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF
Expert Rev Vaccines. 2009 Mar;8(3):333-45.
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E
World J Gastroenterol. 2009 Feb 14;15(6):753-5.
EWI-2wint--a host cell factor inhibiting hepatitis C virus entry.
Schuster C, Baumert TF
J Hepatol. 2009 Jan;50(1):222-4
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.
Zeisel MB, Barth H, Schuster C, Baumert TF
Front Biosci. 2009 Jan 1;14:3274-85.
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1.
Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I
PLoS ONE. 2009;4(2):e4319
Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81
Tian ZF, Shen H, Fu XH, Chen YC, Blum HE, Baumert TF, Zhao XP
World J Gastroenterol. 2009 Jan 14;15(2):240-4.
Toll-Like Receptor 2 Senses Hepatitis C Virus Core Protein but Not Infectious Viral Particles
Hoffmann M, Zeisel MB, Jilg N, Paranhos-Baccala G, Stoll-Keller F, Wakita T, Hafkemeyer P, Blum HE, Barth H, Henneke P, Baumert TF
J Innate Immun. 2009 Aug;1(5):446-54
Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation.
Schramm F, Soulier E, Royer C, Weitten T, Fafi-Kremer S, Brignon N, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoel M, Baumert TF, Stoll-Keller F, Schvoerer E
J Infect Dis. 2008 Dec 1;198(11):1656-66.
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoel M, Dreux M, Baumert TF
Gastroenterology. 2008 Nov;135(5):1719-1728.e1
[Novel strategies for preventing viral hepatitis C recurrence after liver transplantation]
Stoll-Keller F, Fafi-Kremer S, Wolf P, Doffoel M, Baumert T
Bull Acad Natl Med. 2008 Nov;192(8):1657-67; discussion 1667-8.
[Study of hepatitis C virus leukotropism by characterization of viral quasispecies in the liver transplantation setting]
Schramm F, Moenne-Loccoz R, Fafi-Kremer S, Soulier E, Royer C, Weitten T, Brignon N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E
Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):487-91
Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner
Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, Himmelsbach K, Carvajal-Yepes M, Huber R, Wakita T, Schmitt-Graeff A, Royer C, Blum HE, Fischer R, Baumert TF
J Immunol. 2008 Oct 1;181(7):4926-35.
Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films.
Dimitrova M, Affolter C, Meyer F, Nguyen I, Richard DG, Schuster C, Bartenschlager R, Voegel JC, Ogier J, Baumert TF
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16320-5
Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.
Bennour E, Ferrand C, Remy-Martin JP, Certoux JM, Gorke S, Qasim W, Gaspar HB, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E
Hum Gene Ther. 2008 Jul;19(7):699-709.
Host neutralizing responses and pathogenesis of hepatitis C virus infection.
Zeisel MB, Cosset FL, Baumert TF
Hepatology. 2008 Jul;48(1):299-307.
Mouse models for the study of HCV infection and virus-host interactions.
Barth H, Robinet E, Liang TJ, Baumert TF
J Hepatol. 2008 Jul;49(1):134-42
Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells
Hafkemeyer P, Brinkmann U, Brinkmann E, Pastan I, Blum HE, Baumert TF
World J Gastroenterol. 2008 May 14;14(18):2810-7.
The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression.
Wolf M, Dimitrova M, Baumert TF, Schuster C
Nucleic Acids Res. 2008 May;36(9):3054-64
[Neutralizing antibodies in hepatitis C virus infection]
Fafi-Kremer S, Zeisel MB, Schvoerer E, Soulier E, Habersetzer F, Wolf P, Doffoel M, Baumert TF, Stoll-Keller F
Gastroenterol Clin Biol. 2008 May;32(5 Pt 1):491-8
Efficient postexposure prophylaxis by hepatitis A vaccine.
Fafi-Kremer S, Stoll-Keller F, Baumert TF
Hepatology. 2008 Apr;47(4):1416-8.
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells
Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, Hu ZY, Liang TJ, Blum HE, Thimme R, Lambotin M, Baumert TF
J Virol. 2008 Apr;82(7):3466-79
RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle.
Lupberger J, Brino L, Baumert TF
J Hepatol. 2008 Mar;48(3):523-5
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF
Hepatology. 2007 Dec;46(6):1722-31.
Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C.
Baumert TF, Rosler C, Malim MH, von Weizsacker F
Hepatology. 2007 Sep;46(3):682-9.
Hepatitis C virus infection and apoptosis
Fischer R, Baumert T, Blum HE
World J Gastroenterol. 2007 Sep 28;13(36):4865-72.
Neutralizing antibodies in hepatitis C virus infection
Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF
World J Gastroenterol. 2007 Sep 28;13(36):4824-30.
Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease.
Schvoerer E, Soulier E, Royer C, Renaudin AC, Thumann C, Fafi-Kremer S, Brignon N, Doridot S, Meyer N, Pinson P, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Zachary P, Baumert T, Stoll-Keller F
J Infect Dis. 2007 Aug 15;196(4):528-36
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.
Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T
J Virol. 2007 May;81(10):5036-45
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.
Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8427-32
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.
Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
Pathogenesis of hepatitis B virus infection
Baumert TF, Thimme R, von Weizsacker F
World J Gastroenterol. 2007 Jan 7;13(1):82-90.
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection.
Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N, Rauch A, Gerlach JT, Jung MC, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HM
PLoS One. 2007 Jul 25;2(7):e649.
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.
Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF
J Virol. 2006 Nov;80(21):10579-90
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, Pereira CA, Martin JP
J Gen Virol. 2006 Sep;87(Pt 9):2583-93.
Hepatitis C virus entry: molecular biology and clinical implications.
Barth H, Liang TJ, Baumert TF
Hepatology. 2006 Sep;44(3):527-35.
Production of infectious hepatitis C virus in tissue culture: a breakthrough for basic and applied research.
Zeisel MB, Baumert TF
J Hepatol. 2006 Feb;44(2):436-9
A novel target of hepatitis B virus mutations: splicing of surface RNA.
Baumert TF, Kock J, Blum HE
Hepatology. 2005 Jul;42(1):21-3.
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.
Barth H, Cerino R, Arcuri M, Hoffmann M, Schurmann P, Adah MI, Gissler B, Zhao X, Ghisetti V, Lavezzo B, Blum HE, von Weizsacker F, Vitelli A, Scarselli E, Baumert TF
J Virol. 2005 May;79(9):5774-85.
Genetic variants of hepatitis B virus and their clinical relevance.
Baumert TF, Barth H, Blum HE
Minerva Gastroenterol Dietol. 2005 Mar;51(1):95-108.
Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes.
Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grullich C, Nassal M, Liang TJ, Blum HE, von Weizsacker F
Hepatology. 2005 Feb;41(2):247-56.